Breast cancer claims the lives of approximately 670,000 people each year. In 2022, breast cancer was identified as the most common cancer in women in 157 out of 185 countries according to the World Health Organization (WHO) data. More than 2 million women receive a breast cancer diagnosis annually, underscoring the need for early detection and targeted treatment to combat this deadly disease. The US Food and Drug Administration (FDA) has granted approval for the use of Kisqali, also known as ribociclib, in conjunction with hormone therapy for the early-stage treatment of breast cancer. This approval will benefit patients concerned about cancer recurrence. The FDA has authorized ribociclib with an aromatase inhibitor for the adjuvant treatment of adults with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative stage II and III early breast cancer at high risk of recurrence. Additionally, the FDA has approved the ribociclib and letrozole co-pack for the same indication. Kisqali, a selective cyclin-dependent kinase inhibitor, works by inhibiting certain proteins that can stimulate the excessive growth and division of cancer cells. Administered orally, Kisqali is prescribed for three weeks followed by a one-week break, and this cycle continues for three years. The medication can be taken with or without food, with a recommended daily dose of 400 mg.Editor's note: Kisqali - Side Effects

Common side effects of Kisqali medication include a low white blood cell count, known as neutropenia, where there are reduced levels of neutrophils in the blood. Neutrophils are important for fighting infections in the body. Other potential side effects of Kisqali may include liver-related problems and interstitial lung disease or pneumonitis.

Breast Cancer: Warning Signs You Shouldn't Overlook